 Novel benzylalcohol derivatives and processes for preparing the same |
| What we claim is: 1. A compound of the formula: ##STR11## wherein R is a lower alkyl group having 1-... |
|
| Method of use of bicycloheptane substituted prostaglandin analogs as cardiovascular agents |
| What is claimed is: 1. A method of inhibiting arachidonic acid-induced platelet aggregation and ... |
|
| Dihydropyridine derivatives and pharmaceutical composition thereof |
| OF THE INVENTION This invention relates to dihydropyridine derivatives represented by the formula (... |
|
| Use of fedotozine in the treatment of functional states of intestinal obstructions |
| We claim: 1. Process for inhibiting functional ileus in a patient, which consists of administering ... |
|
| Manufacture of pharmaceutical dosage forms |
| OF THE INVENTION The present invention is directed to solid, unit dosage forms primarily for oral ... |
|
| Device comprising liner for protecting fluid sensitive medicament |
| OF THE DRAWING FIGURES Turning now to the drawings in detail, which are examples of various ... |
|
| In situ active compound assembly |
| I claim: 1. A method to modify a target condition contained within an environment with a conjugate ... |
|
| Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein |
| The invention is directed to a method for the prophylaxis or treatment of an animal for systemic ... |
|
|
Water dispersible gemfibrozil compositions
| Details |
Inventors: Ghebre-Sellassie, Isaac; Gordon, Robert H.; Iyer, Uma; Fawzi, Mahdi B.;
Assignee: Warner-Lambert Company (Ann Arbor, MI)
Primary Examiner: Page; Thurman K.
Assistant Examiner:
Attorney, Agent or Firm: Mathews, Woodbridge & Collins
A water-dispersible formulation of gemfibrozil comprising finely divided particles of pure gemfibrozil uniformly coated with a mixture of a wax and at least one hydrophilic material, the coated particles in turn being overcoated with a minor amount of a surfactant. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A water-dispersible formulation of gemfibrozil comprising finely divided particles of pure gemfibrozil uniformly coated with a mixture of a wax and at least one hydrophilic material selected from the group consisting of fatty acid alcohols, fatty acid esters, polyols, cellulose derivatives, and vinyl derivatives, the ratio of wax to hydrophilic material being from about 1:0.
1 to about 0.
1:1, said coated particles in trun being overcoated with an amount of a surfactant sufficient to improve the dispersibility of the formulation in water.
2.
A water-dispersible formulation of gemfibrozil according to claim 1 wherein a first portion of the finely divided particles of pure gemfibrozil uniformly coated with a mixture of a wax and stearyl alcohol to provide relatively immediate release and a second portion of the finely divided particles of pure gemfibrozil uniformly coated with a mixture of a wax and hydrogenated castor oil to provide relatively sustained release.
3.
A water-dispersible formulation of gemfibrozil according to claim 1 wherein the hydrophilic material is stearyl alcohol.
4.
A water-dispersible formulation of gemfibrozil according to claim 1 wherein the surfactant is sodium lauryl sulfate.
Description:
The present invention relates to a water-dispersible formulation of gemfibrozil.
Background Gemfibrozil, or 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid, is a widely used antihyperlipoproteinemic agent which, because of the required large dose, generally is administered several times a day in the form of multiple capsules.
Although it would be desirable to administer the agent in a water-dispersible formulation, this approach heretofore has been unattainable because of the unpleasant burning after-taste which it produces in the buccal mucosa.
It also would be beneficial to provide such water-dispersible formulations with sustained release properties so as to reduce the number of times the drug must be administered.
British Application No
|
| Related patents |
|
|
Method and composition for enhancing the effect of indirect-acting sympathomimetic amines
OF SPECIFIC EMBODIMENTS In accordance with this invention, tyrosine or a tyrosine precursor such as phenylalanine is administered concomitnatly with an indirect-acting ...
|
|
|
1-azabicycloalkane derivatives, their preparation process and their use as medicaments
What is claimed is: 1. A compound of formula (I) ##STR5## in which n represents the number 1, R.sub.1 and R.sub.2, identical or different represent hydrogen or an ...
|
|
|
Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration
OF THE INVENTION The novel method of treatment of neurodegeneration of this invention comprises the administration to a patient in need of such treatment with an ...
|
|
|
Iron citrate complex, process for its production, and its pharmaceutical
We claim: 1. An iron citrate micellar complex, which is a brown solid having the properties set out below: (a) average composition by weight of about: 10.6% carbon, 2.62%...
|
|
|
Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same
OF INVENTION The 4,5-bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazoles of the present invention have the formula (I) as described hereinbefore. In the formula (I), the ...
|
|
|
Specifically .beta.-.beta. cross-linked hemoglobins and method of preparation
The present invention provides a modified hemoglobin comprising hemoglobin which is cross-linked with a cross-linking reagent, said cross-linking reagent being selected ...
|
|
|
Apparatus for manufacturing granulated material
The invention proceeds from the consideration that it is not possible to reduce the width of the slit, especially at high production rates i.e., at high relative ...
|
|
|
Substituted and bridged pyridines useful as calcium channel blockers
OF THE INVENTION The specific substituted and bridged pyridine compounds of this invention are represented by the following general structural formula (I): ##STR1## ...
|
|
|
Ace inhibitors in macular degeneration
OF THE INVENTION The novel method of treatment of senile macular degeneration of this invention comprises the administration to a patient in need of such treatment of ...
|
|
|
Derivatives of 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonines and -1,4-benzoxazonines, processes for their production and their use as pharmaceuticals
We claim: 1. 2,3,4,5,6,7-Hexahydro-2,7-methano-1,5-benzoxazonine and -1,4-benzoxazonine compounds, of the formula ##STR15## wherein: R.sub.1 is hydrogen or C.sub.1 -C....
|
|
|
Vasodialators 
